Show simple item record

B04 Effects of nanoliposomal irinotecan (nal-IRI; MM-398) +/- 5-fluorouracil and leucavorin (5-FU/LV) on quality of life (QoL) in patients (pts) with metastatic pancreatic adenocarcinoma (mPAC) previously treated with gemcitabine-based therapy: results from the phase 3 NAPOLI-1 study.

dc.contributor.authorMelisi, D
dc.contributor.authorSiveke, J
dc.contributor.authorBlanc, J
dc.contributor.authorVon Hoff, D
dc.contributor.authorWang-Gillam, A
dc.contributor.authorChen, L
dc.contributor.authorBecker, C
dc.contributor.authorMamlouk, K
dc.contributor.authorDe Jong, F
dc.contributor.authorHubner, Richard A
dc.date.accessioned2017-04-24T17:07:24Z
dc.date.available2017-04-24T17:07:24Z
dc.date.issued2016-09-21
dc.identifier.citationB04 Effects of nanoliposomal irinotecan (nal-IRI; MM-398) ± 5-fluorouracil and leucavorin (5-FU/LV) on quality of life (QoL) in patients (pts) with metastatic pancreatic adenocarcinoma (mPAC) previously treated with gemcitabine-based therapy: results from the phase 3 NAPOLI-1 study. 2016, 27 (suppl_4): iv18 Annals of Oncologyen
dc.identifier.issn0923-7534
dc.identifier.issn1569-8041
dc.identifier.doi10.1093/annonc/mdw333.04
dc.identifier.urihttp://hdl.handle.net/10541/620284
dc.language.isoenen
dc.relation.urlhttps://academic.oup.com/annonc/article/27/suppl_4/iv18/2770148/B04Effects-of-nanoliposomal-irinotecan-nal-IRI-MMen
dc.rightsArchived with thanks to Annals of Oncologyen
dc.titleB04 Effects of nanoliposomal irinotecan (nal-IRI; MM-398) +/- 5-fluorouracil and leucavorin (5-FU/LV) on quality of life (QoL) in patients (pts) with metastatic pancreatic adenocarcinoma (mPAC) previously treated with gemcitabine-based therapy: results from the phase 3 NAPOLI-1 study.en
dc.typeMeetings and Proceedingsen
dc.contributor.departmentUniversità di Verona, Veronaen
dc.identifier.journalAnnals of Oncologyen


This item appears in the following Collection(s)

Show simple item record